- Home
- PML vs NPCE Comparison
PML vs NPCE Comparison
Compare PML & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$16.07
Company Overview
Basic Information| Metric | PML | NPCE |
|---|---|---|
| Founded | 2002 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.0M | 514.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PML | NPCE |
|---|---|---|
| Price | $7.79 | $16.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.14 |
| AVG Volume (30 Days) | 188.0K | ★ 254.0K |
| Earning Date | 01-01-0001 | 03-03-2026 |
| Dividend Yield | ★ 5.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $94,864,000.00 |
| Revenue This Year | N/A | $25.30 |
| Revenue Next Year | N/A | $0.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $6.92 | $7.56 |
| 52 Week High | $9.46 | $18.98 |
Technical Indicators
Market Signals| Indicator | PML | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 67.44 | 49.25 |
| Support Level | $7.61 | $14.88 |
| Resistance Level | $7.67 | $17.44 |
| Average True Range (ATR) | 0.06 | 0.69 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 80.33 | 42.36 |
Price Performance
Historical Comparison PML
NPCE
About PML Pimco Municipal Income Fund II of Beneficial Interest
PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.